Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab Lorenz Kocheise; Jan Kempski; Yunhe Tang; Lorenz Balcar; Victoria Berger; Miriam Tomczak; Joao Gorgulho; Ramsha Masood; Franziska Giehren; Constantin Schmidt; Jan P. Sutter; Thorben W. Fruendt; Francesca Pagani; Sophie Wulf; Julian Kött; Saskia Domanig; Anastasios Giannou; Tanja Bedke; Jöran Lücke; Tao Zhang; Siwen Zhang; Andres Machicote; Ansgar W. Lohse; Marianna Alunni-Fabbroni; Jens Ricke; Najib Ben Khaled; Matthias Pinter; Bernhard Scheiner; Samuel Huber; Johann von Felden; Ignazio Piseddu; Kornelius Schulze;

Serum bilirubin concentrations and their association with clinical and radiological outcomes in multiple sclerosis: A large cohort study Tomá¿ Uher; Pavlína Kleinová; Jana Woronyczová; Lubomír ¿t¿pánek; Manuela Van¿¿ková; Jan Krásenský; Renata Cífková; Dana Horáková; Eva Havrdová; David Hoskovec; Martin Lení¿ek; Libor Vítek;

From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease Mi Zhou; Jianyu Lv; Xinli Chen; Yujie Shi; Guanqun Chao; Shuo Zhang;